Recent NewsOptimapharm Featured in STAT News and Smarter Capital Allocation in Early Phase Oncology
Recent NewsOptimapharm Featured in STAT News and Smarter Capital Allocation in Early Phase Oncology
Recent NewsOptimapharm Featured in STAT News and Smarter Capital Allocation in Early Phase Oncology
Recent NewsOptimapharm Featured in STAT News and Smarter Capital Allocation in Early Phase Oncology
Optimapharm
Partnered on
86
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
87
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
Approved Therapies
Contracted with
4,000+
Investigator Sites
Enrolled
43,000+
Patients

1,003Clinical Projects across40Countries

Distribution of Optimapharm projects across clinical trial Phases I-IV
Distribution of Optimapharm projects by drug mechanism of action

Optimapharm is dedicated to helping innovative therapies reach patients, delivering over 1000 global Phase I–IV clinical projects with a strong focus on quality, service, and scientific rigour. We partner closely with small, emerging, and commercial biotech organisations, providing a high level of customer attention, responsiveness, and expert guidance throughout the development lifecycle. By combining deep clinical expertise with a service-driven approach, we help transform promising innovations into therapies that deliver real hope and meaningful outcomes for patients worldwide.

Therapeutic Expertise

Cardiology
Cardiology Text
Immunology
Immunology Text
Dermatology
Dermatology Text
Oncology
Oncology Text
Neurology
Neurology Text

Functional Capabilities

Regulatory and Ethics
Regulatory and Ethics
Clinical Monitoring
Clinical Monitoring
Medical Monitoring
Medical Monitoring
Project Management
Project Management
Data Management
Data Management
Biostatistics
Biostatistics
Medical Writing
Medical Writing
Pharmacovigilance
Pharmacovigilance